Clinical features of liver injury induced by antitumor drugs:An analysis of 56 cases

Zhang HuiJuan; Shi ZuXuan; Zhao LanFang; Gao TianHui; Li Jian

doi:10.3969/j.issn.1001-5256.2019.03.024

Volume 35 Issue 3

Mar. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(3): 574-578

PDF( 2150 KB)

Clinical features of liver injury induced by antitumor drugs:An analysis of 56 cases

DOI: 10.3969/j.issn.1001-5256.2019.03.024

Department of Medical Care, The First Affiliated Hospital of Hainan Medical College

Research funding:

Published Date: 2019-03-20

Abstract

Abstract

Objective To investigate the clinical features of drug-induced liver injury ( DILI) caused by antitumor drugs during the treat-ment of malignant tumors. Methods A retrospective analysis was performed for the clinical data of 56 patients who were diagnosed with ma-lignant tumors in Henan Provincial People's Hospital from January 2015 to December 2016 and experienced DILI during the treatment withantitumor drugs, including sex, age, type of primary tumor, hepatotropic virus infection, liver function, type of chemotherapeutics, onsettime of liver injury, application of liver-protecting drugs, and outcome of liver injury. Results Among the 56 patients with DILI caused byantitumor drugs, 30 ( 53. 6%) had hepatocellular injury, and 45 ( 80. 4%) had mild liver injury. FOLFOX, GP/DP, and CHOP were themost common regimens for DILI, and of all 56 patients, 50 ( 89. 3%) had DILI caused by multiple drugs. Platinum-based drugs, anti-microtubule agents, and alkylating agents were the common drugs causing DILI. Of all 56 patients, 35 ( 62. 5%) developed DILI within 1-2 weeks after medication. Conclusion DILI caused by antitumor drugs mainly has a mild degree and hepatocellular injury type is the mostcommon clinical type. Platinum-based antitumor drugs and related chemotherapeutic regimens are the most common drugs for DILI. A com-bination of multiple antitumor drugs is more likely to cause DILI, and patients with such DILI often have a good prognosis.
- antineoplastic agents,
- drug-induced liver injury

FullText(HTML)

References(28)

References

[1] CHEN W, ZHENG R, ZUO T, et al. National cancer incidenceand mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28 (1) :1-11.

[2] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in Chi-na, 2015[J]. CA Cancer J Clin, 2016, 66 (2) :115-132.

[3] REN J, ZHOU XN. Development of drug induced liver injury inanti-tumor treatment[J]. Chin J Drug Appl Monit, 2012, 9 (6) :309-313. (in Chinese) 任军, 周心娜.抗肿瘤药物肝损伤研究进展[J].中国药物应用与监测, 2012, 9 (6) :309-313.

[4] VINCENZI B, ARMENTO G, SPALATO CERUSO M, et al, Drug-induced hepatotoxicity in cancer patients-implication for treat-ment[J]. Expert Opin Drug Saf, 2016, 15 (9) :1219-1238.

[5] Drug-induced Liver Disease Study Group, Chinese Society ofHepatology, Chinese Medical Association. Guidelines for themanagement of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[6] CHEN CW. Research advances in drug-induced liver injuryand existing problems in China[J]. J Clin Hepatol, 2018, 34 (6) :1147-1151. (in Chinese) 陈成伟.药物性肝损伤的研究进展及我国存在的问题[J].临床肝胆病杂志, 2018, 34 (6) :1147-1151.

[7] SHEN T, HUANG X, WANG YY, et al. Current status of epide-miological study on drug-induced liver injury in China[J]. JClin Hepatol, 2018, 34 (6) :1152-1155. (in Chinese) 沈弢, 黄昕, 王誉雅, 等.我国药物性肝损伤流行病学研究现状[J].临床肝胆病杂志, 2018, 34 (6) :1152-1155.

[8] YUAN Y, LI J, LAN L, et al. Analysis of clinical characteristicsamong 245 cases of patients with drug-induced liver damage[J]. Chronic Pathematology J, 2015, 16 (2) :170-172. (inChinese) 袁媛, 李健, 兰玲, 等. 245例药物性肝损伤病例的临床流行病学特征描述[J].慢性病学杂志, 2015, 16 (2) :170-172.

[9] ZHU CW, WANG HN, YUAN JL, et al. Clinical features of drug-induced liver injury:An analysis of 445 cases[J]. J Clin Hepatol, 2018, 34 (2) :354-358. (in Chinese) 朱春雾, 王海南, 袁继丽, 等. 445例药物性肝损伤的临床分析[J].临床肝胆病杂志, 2018, 34 (2) :354-358.

[10] THATISHETTY AV, AGRESTI N, O'BRIEN CB. Chemotherapy-induced hepatotoxicity[J]. Clin Liver Dis, 2013, 17 (4) :671-686.

[11] BAHIRWANI R, REDDY KR. Drug-induced liver injury due tocancer chemotherapeutic agents[J]. Semin Liver Dis, 2014, 34 (2) :162-171.

[12] LEISE MD, POTERUCHA JJ, TALWALKAR JA. Drug-inducedliver injury[J]. Mayo Clin Proc, 2014, 89 (1) :95-106.

[13] YAN SY, FAN JG. Effect of antineoplastic drugs on liver andtheir application in patients with liver diseases[J]. World ClinDrugs, 2011, 32 (9) :513-517. (in Chinese) 颜士岩, 范建高.抗肿瘤药物对肝脏的影响及其在肝病患者中的应用[J].世界临床药物, 2011, 32 (9) :513-517.

[14] HU XY, SUN J, PENG J. New considerations in antiviral thera-py for special populations with chronic hepatitis B[J]. J ClinHepatol, 2016, 32 (11) :2054-2057. (in Chinese) 胡晓云, 孙剑, 彭劼.乙型肝炎特殊人群抗病毒治疗的新认识[J].临床肝胆病杂志, 2016, 32 (11) :2054-2057.

[15] KIM E, YUNE S, HA JM, et al. Hepatitis B virus reactivation dur-ing anticancer chemotherapy in patients with past hepatitis B virusinfection[J]. Hepatogastroenterology, 2014, 61 (134) :1704-1711.

[16] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinicalpractice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int, 2016, 10 (1) :1-98.

[17] WU SX, XU HY, HUANG HC, et al. Clinical analysis of liver in-jury and hepatitis B virus reactivation after chemotherapy inHBsAg-positive patients with malignant tumors[J]. J ClinHepatol, 2016, 32 (1) :110-113. (in Chinese) 吴盛喜, 许鸿鹞, 黄河澄, 等. HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析[J].临床肝胆病杂志, 2016, 32 (1) :110-113.

[18] XU L, TU Z, XU G, et al. Epirubicin directly promotes hepati-tis B virus (HBV) replication in stable HBV-expressing celllines:A novel mechanism of HBV reactivation following anti-cancer chemotherapy[J]. Mol Med Rep, 2014, 9 (4) :1345-1350.

[19] SANAGAWA A, HOTTA Y, KATAOKA T, et al. Hepatitis B in-fection reported with cancer chemotherapy:Analyzing the USFDA adverse event reporting system[J]. Cancer Med, 2018, 7 (6) :2269-2279.

[20] YANG LH, LIU R, ZENG QY, et al. Association of methyle-netetrahydrofolate reductase gene polymorphism in childrenwith acute lymphoblastic leukemia and adverse reaction ofhigh dose methotrexate[J]. J Appl Clin Pediatr, 2012, 27 (6) :440-442. (in Chinese) 杨丽华, 刘茹, 曾其毅, 等.急性淋巴细胞白血病患儿亚甲基四氢叶酸还原酶基因多态性与大剂量甲氨蝶呤不良反应的相关性[J].实用儿科临床杂志, 2012, 27 (6) :440-442.

[21] SCRIPTURE CD, FIGG WD. Drug interactions in cancer thera-py[J]. Nat Rev Cancer, 2006, 6 (7) :546-558.

[22] CAMPEN CJ, VOGEL WH, SHAH PJ. Managing drug interac-tions in cancer therapy:A guide for the advanced practitioner[J]. J Adv Pract Oncol, 2017, 8 (6) :609-620.

[23] TEO YL, HO HK, CHAN A. Formation of reactive metabolitesand management of tyrosine kinase inhibitor-induced hepato-toxicity:A literature review[J]. Expert Opin Drug Metab Toxi-col, 2015, 11 (2) :231-242.

[24] LOU XE, CHEN M, YANG B. Research progress in toxicologyof molecular targeted anticancer drugs[J]. J Zhejiang Univ:Med Sci, 2015, 44 (5) :473-478. (in Chinese) 娄小娥, 陈敏, 杨波.分子靶向抗肿瘤药物的毒性研究进展[J].浙江大学学报:医学版, 2015, 44 (5) :473-478.

[25] PAECH F, BOUITBIR J, KRHENBHL S. Hepatocellular tox-icity associated with tyrosine kinase inhibitors:Mitochondrialdamage and inhibition of glycolysis[J]. Front Pharmacol, 2017, 8:367.

[26] SHAH RR, MORGANROTH J, SHAH DR. Hepatotoxicity of tyro-sine kinase inhibitors:Clinical and regulatory perspectives[J].Drug Saf, 2013, 36 (7) :491-503.

[27] Chinese Society of Infectious Diseases, Chinese Medical As-sociation, Expert Committee for Prevention and Managementof Liver Inflammation. Prevention and management of liver in-flammation:An expert consensus in China[J]. Chin J Clin In-fect Dis, 2014, 7 (1) :4-12. (in Chinese) 中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会.肝脏炎症及其防治专家共识[J].中华临床感染病杂志, 2014, 7 (1) :4-12.

[28] SUN YJ, QI WX, YAO Y. Prevention and treatment of glutathi-one in chemotherapy-induced liver injury[J]. China Cancer, 2015, 24 (1) :57-63. (in Chinese) 孙元珏, 祁伟祥, 姚阳.还原型谷胱甘肽与肿瘤化疗相关性肝损伤的防治[J].中国肿瘤, 2015, 24 (1) :57-63.

Relative Articles

[1]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[2]	Lu Qian, Zhu Li, Cheng Xin, Huang Hua, Chen Zhong. Expression of proteasome subunit beta type 4 in hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 372-376. doi: 10.3969/j.issn.1001-5256.2020.02.028
[3]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[4]	Ye YingJian, Liu Bo, Chen Wei, Li QiongXia. Prognosis and staging system analysis of hepatocellular carcinoma patients with negative serum alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2019, 35(3): 535-541. doi: 10.3969/j.issn.1001-5256.2019.03.017
[5]	Zang YouYa, Long PeiYun, Han ZhiWei, Wang Huan, Ruan JingSheng, Huang Shan, Wu GuoBin, Chen Chuang. Establishment and verification of a nomogram for predicting patient prognosis after hepatectomy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(10): 2225-2230. doi: 10.3969/j.issn.1001-5256.2019.10.019
[6]	Chen Chuang, Long PeiYun, Chen Jie, Wang Pan, Huang QingYun, Zang YouYa, Deng GuoYu, Lin DongYi, Wang ZongYu. Value of Barcelona Clinic Liver Cancer staging system versus Hong Kong Liver Cancer staging system in predicting the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(3): 530-534. doi: 10.3969/j.issn.1001-5256.2019.03.016
[7]	Tang Ling, Qiu LuDie, Qin Wen, Wu Gang. Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2019.09.019
[8]	Luo Hao, Huang Jun. Clinical value of albumin-bilirubin grade in evaluating the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1608-1612. doi: 10.3969/j.issn.1001-5256.2019.07.040
[9]	He YaJing, Zhang ZhiMing, He WeiMeng, Hou JinLin. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1002-1007. doi: 10.3969/j.issn.1001-5256.2019.05.014
[10]	Zhu Feng, Feng XiaoHai, An Yue. Association between the expression of somatostatin receptors and pathological features, prognosis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(2): 314-320. doi: 10.3969/j.issn.1001-5256.2018.02.019
[11]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[12]	Xia DongDong, Wang EnXin, Wang WenJun, Bai Wei, Yuan Jie, Han GuoHong. Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2017, 33(6): 1120-1125. doi: 10.3969/j.issn.1001-5256.2017.06.021
[13]	Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 80-83. doi: 10.3969/j.issn.1001-5256.2016.01.013
[14]	Wang XianBo, Gao FangYuan, Liu Yao. Neutrophil- lymphocyte ratio: a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 649-652. doi: 10.3969/j.issn.1001-5256.2016.04.007
[15]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[16]	Li Peng, Zhai Yun, Zhang ShiBin, Li Lei, Ding HuiGuo. Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 721-724. doi: 10.3969/j.issn.1001-5256.2015.05.021
[17]	Wang JianGang, Li HuaCheng, Fei XinYing. Application of metabolomics in research on biomarkers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(8): 836-838. doi: 10.3969/j.issn.1001-5256.2014.08.039
[18]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006
[19]	Zhang LiJun, Jia XiaoFang, Teng ZhenLin, Cheng NengNeng. Biomarkers of liver cancer related to hepatitis B virus selected by proteomics[J]. Journal of Clinical Hepatology, 2011, 27(5): 553-557.
[20]	Ren YiBin, Wang HongYang. The progress of diagnostic marker in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2010, 26(4): 358-360+364.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	顾智文. 射频消融术联合奥沙利铂加卡培他滨方案用于结直肠癌术后肝转移患者的临床价值. 大医生. 2024(01): 25-28 .
2.	刘炫鳞，买佳琪，马文兵. 脾多肽注射液联合西妥昔、mFOLFOX6方案对直肠癌肝转移患者生存质量及TRF1、TRF2表达的影响. 临床医学研究与实践. 2023(25): 29-32 .
3.	林守英，周庄，刘丽雅. 薏苡附子败酱散联合XELOX方案对结直肠癌患者免疫功能、肠道菌群的影响. 实用中西医结合临床. 2023(21): 37-40 .
4.	张洋，杨帆，王景景. 沙利度胺联合XELOX方案化疗治疗转移性结直肠癌的疗效及对生存率的影响. 癌症进展. 2022(07): 727-730 .
5.	苏华冠，谢礼福，刘奕武，赖光芒. 腹腔镜下结直肠癌切除术联合肝转移瘤射频消融术治疗结直肠癌肝转移. 中国肝脏病杂志(电子版). 2021(02): 13-18 .
6.	王强. 经皮肝射频消融术联合经导管肝动脉灌注化疗治疗晚期结直肠癌多发肝转移瘤患者的效果. 中国民康医学. 2021(23): 19-22 .
7.	刘信，刘放，刘也夫，谢峰，张睿. 术中开腹彩超引导下射频与经皮CT引导射频治疗结直肠癌肝转移疗效比较研究. 临床军医杂志. 2020(02): 167-169 .
8.	高岩，蓝宇，贾纯增. 内镜黏膜下剥离术治疗早期结直肠癌及癌前病变临床效果观察. 临床军医杂志. 2020(06): 668-671+675 .
9.	吕厚宽，庄文辉，刘晓晖，郭泽才，刘琪. 卡培他滨联合奥沙利铂治疗直肠癌的临床疗效研究. 长春中医药大学学报. 2020(04): 741-744 .
10.	李江，候宇，蔡晓蓓，徐承雷，易根发. 基于限制性肝段切除手术的局部治疗模式改善结直肠癌术后肝脏寡转移的预后分析. 临床肝胆病杂志. 2020(08): 1763-1767 . 本站查看
11.	彭文杰. AFP、CCL2和HP在结直肠癌肝转移诊断中的临床应用研究. 国际生物医学工程杂志. 2019(05): 414-418 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1808) PDF downloads(352)

Clinical features of liver injury induced by antitumor drugs:An analysis of 56 cases

DOI: 10.3969/j.issn.1001-5256.2019.03.024